InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,176.11
(
0.44%
)
Post# of 251717
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 199069

Thursday, 01/14/2016 7:55:18 PM

Thursday, January 14, 2016 7:55:18 PM

Post# of 251717
Re: ABBV’s Humira patents/AMGN-AGN FoB

Despite the unfavorable ruling in the IPR at the USPTO, AMGN/AGN still can—and probably will—launch its Humira FoB in the US market (pending FDA approval) and take its chances in court (#msg-118766059). Knocking out ABBV’s Humira patents via the IPR was Plan A… prevailing in a patent trial is Plan B. There’s also a possibility for a settlement.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up